
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep Ltd is advancing its product candidate, eftilagimod alfa (efti), through a registrational Phase three clinical trial for first-line non-small cell lung cancer (1L NSCLC), demonstrating significant efficacy improvements in patients with lower PD-L1 expression. The drug has shown to increase overall response rates in less responsive populations, specifically boosting the ORR by 22.2% over historical rates, highlighting its potential to enhance treatment outcomes. Additionally, efti's strong patent portfolio and its capacity for combinability with existing therapies present opportunities for Immutep to expand its influence within the competitive oncology market.
Bears say
Immutep Ltd's stock outlook is negatively impacted by the declining confidence in its lead product candidate, eftilagimod alfa (efti), following underwhelming clinical results that have led to a reduced probability of success in non-small cell lung cancer (NSCLC) to 30%. The overall efficacy results from the INSIGHT-003 trial are anticipated to be inferior compared to historical benchmarks, particularly due to a higher proportion of patients with low tumor proportion scores (TPS<1%), which may exacerbate concerns around treatment effectiveness. Additionally, the mixed efficacy results from LAG-3 antagonists in lung cancer contribute to a perceptual headwind, as these therapies are not widely regarded as transformative, further diminishing investor confidence.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares